


CLAIMS

1. A compound of formula (I):



wherein

A is absent or is (CH<sub>2</sub>)<sub>2</sub>;

R<sup>1</sup> is C<sub>1-8</sub> alkyl, C(O)NR<sup>10</sup>R<sup>11</sup>, C(O)<sub>2</sub>R<sup>12</sup>, NR<sup>13</sup>C(O)R<sup>14</sup>, NR<sup>15</sup>C(O)NR<sup>16</sup>R<sup>17</sup>, NR<sup>18</sup>C(O)<sub>2</sub>R<sup>19</sup>, heterocyclyl, aryl or heteroaryl;

R<sup>10</sup>, R<sup>13</sup>, R<sup>15</sup>, R<sup>16</sup> and R<sup>18</sup> are hydrogen or C<sub>1-6</sub> alkyl;

R<sup>11</sup>, R<sup>12</sup>, R<sup>14</sup>, R<sup>17</sup> and R<sup>19</sup> are C<sub>1-8</sub> alkyl (optionally substituted by halo, hydroxy, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkoxy, C<sub>3-6</sub> cycloalkyl (optionally substituted by halo), C<sub>5-6</sub>

cycloalkenyl, S(C<sub>1-4</sub> alkyl), S(O)(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), heteroaryl, aryl,

heteroaryloxy or aryloxy), aryl, heteroaryl, C<sub>3-7</sub> cycloalkyl (optionally substituted by halo or C<sub>1-4</sub> alkyl), C<sub>4-7</sub> cycloalkyl fused to a phenyl ring, C<sub>5-7</sub> cycloalkenyl, or,

heterocyclyl (itself optionally substituted by oxo, C(O)(C<sub>1-6</sub> alkyl), S(O)<sub>k</sub>(C<sub>1-6</sub> alkyl), halo or C<sub>1-4</sub> alkyl); or R<sup>11</sup>, R<sup>12</sup>, R<sup>14</sup> and R<sup>17</sup> can also be hydrogen;

or R<sup>10</sup> and R<sup>11</sup>, and/or R<sup>16</sup> and R<sup>17</sup> may join to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by C<sub>1-6</sub> alkyl, S(O)<sub>k</sub>(C<sub>1-6</sub> alkyl) or C(O)(C<sub>1-6</sub> alkyl);

R<sup>2</sup> C<sub>1-6</sub> alkyl, phenyl, heteroaryl or C<sub>3-7</sub> cycloalkyl;

R<sup>3</sup> H or C<sub>1-4</sub> alkyl;

R<sup>4</sup> is aryl or heteroaryl;

n is 2, 3 or 4;

unless specified otherwise aryl, phenyl and heteroaryl moieties are independently

optionally substituted by one or more of halo, cyano, nitro, hydroxy, OC(O)NR<sup>20</sup>R<sup>21</sup>, NR<sup>22</sup>R<sup>23</sup>, NR<sup>24</sup>C(O)R<sup>25</sup>, NR<sup>26</sup>C(O)NR<sup>27</sup>R<sup>28</sup>, S(O)<sub>2</sub>NR<sup>29</sup>R<sup>30</sup>, NR<sup>31</sup>S(O)<sub>2</sub>R<sup>32</sup>,

C(O)NR<sup>33</sup>R<sup>34</sup>, CO<sub>2</sub>R<sup>36</sup>, NR<sup>37</sup>CO<sub>2</sub>R<sup>38</sup>, S(O)<sub>q</sub>R<sup>39</sup>, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl,

C<sub>3-10</sub> cycloalkyl, C<sub>1-6</sub> haloalkyl, C<sub>1-6</sub> alkoxy(C<sub>1-6</sub>)alkyl, C<sub>1-6</sub> alkoxy, C<sub>1-6</sub> haloalkoxy,

phenyl, phenyl(C<sub>1-4</sub>)alkyl, phenoxy, phenylthio, phenylS(O), phenylS(O)<sub>2</sub>, phenyl(C<sub>1-</sub>

<sub>4</sub>)alkoxy, heteroaryl, heteroaryl(C<sub>1-4</sub>)alkyl, heteroaryloxy or heteroaryl(C<sub>1-4</sub>)alkoxy;

wherein any of the immediately foregoing phenyl and heteroaryl moieties are

optionally substituted with halo, hydroxy, nitro,  $S(C_{1-4} \text{ alkyl})$ ,  $S(O)(C_{1-4} \text{ alkyl})$ ,  $S(O)_2(C_{1-4} \text{ alkyl})$ ,  $S(O)_2NH_2$ ,  $S(O)_2NH(C_{1-4} \text{ alkyl})$ ,  $S(O)_2N(C_{1-4} \text{ alkyl})_2$ , cyano,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $C(O)NH_2$ ,  $C(O)NH(C_{1-4} \text{ alkyl})$ ,  $C(O)N(C_{1-4} \text{ alkyl})_2$ ,  $CO_2H$ ,  $CO_2(C_{1-4} \text{ alkyl})$ ,  $NHC(O)(C_{1-4} \text{ alkyl})$ ,  $NHS(O)_2(C_{1-4} \text{ alkyl})$ ,  $CF_3$  or  $OCF_3$ ;

5 unless otherwise stated heterocyclyl is optionally substituted by  $C_{1-6}$  alkyl [optionally substituted by phenyl {which itself optionally substituted by halo,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy, cyano, nitro,  $CF_3$ ,  $OCF_3$ ,  $(C_{1-4} \text{ alkyl})C(O)NH$ ,  $S(O)_2NH_2$ ,  $C_{1-4}$  alkylthio,  $S(O)(C_{1-4} \text{ alkyl})$  or  $S(O)_2(C_{1-4} \text{ alkyl})$ } or heteroaryl {which itself optionally substituted by halo,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy, cyano, nitro,  $CF_3$ ,  $(C_{1-4} \text{ alkyl})C(O)NH$ ,  $S(O)_2NH_2$ ,  $C_{1-4}$  alkylthio,  $S(O)(C_{1-4} \text{ alkyl})$  or  $S(O)_2(C_{1-4} \text{ alkyl})$ }], phenyl {optionally substituted by halo,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy, cyano, nitro,  $CF_3$ ,  $OCF_3$ ,  $(C_{1-4} \text{ alkyl})C(O)NH$ ,  $S(O)_2NH_2$ ,  $C_{1-4}$  alkylthio,  $S(O)(C_{1-4} \text{ alkyl})$  or  $S(O)_2(C_{1-4} \text{ alkyl})$ }, heteroaryl {optionally substituted by halo,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy, cyano, nitro,  $CF_3$ ,  $(C_{1-4} \text{ alkyl})C(O)NH$ ,  $S(O)_2NH_2$ ,  $C_{1-4}$  alkylthio,  $S(O)(C_{1-4} \text{ alkyl})$  or  $S(O)_2(C_{1-4} \text{ alkyl})$ },  $S(O)_2NR^{40}R^{41}$ ,  $C(O)R^{42}$ ,  $C(O)_2(C_{1-6}$  alkyl) (such as *tert*-butoxycarbonyl),  $C(O)_2(\text{phenyl}(C_{1-2} \text{ alkyl}))$  (such as benzyloxycarbonyl),  $C(O)NHR^{43}$ ,  $S(O)_2R^{44}$ ,  $NHS(O)_2NHR^{45}$ ,  $NHC(O)R^{46}$ ,  $NHC(O)NHR^{47}$  or  $NHS(O)_2R^{48}$ , provided none of these last four substituents is linked to a ring nitrogen;

$k$ ,  $l$ ,  $p$  and  $q$  are, independently, 0, 1 or 2;

20  $R^{20}$ ,  $R^{22}$ ,  $R^{24}$ ,  $R^{26}$ ,  $R^{27}$ ,  $R^{29}$ ,  $R^{31}$ ,  $R^{33}$ ,  $R^{37}$  and  $R^{40}$  are, independently, hydrogen or  $C_{1-6}$  alkyl;


$R^{21}$ ,  $R^{23}$ ,  $R^{25}$ ,  $R^{28}$ ,  $R^{30}$ ,  $R^{32}$ ,  $R^{34}$ ,  $R^{36}$ ,  $R^{38}$ ,  $R^{39}$ ,  $R^{41}$ ,  $R^{42}$ ,  $R^{43}$ ,  $R^{44}$ ,  $R^{45}$ ,  $R^{46}$ ,  $R^{47}$  and  $R^{48}$  are, independently,  $C_{1-6}$  alkyl (optionally substituted by halo, hydroxy,  $C_{1-6}$  alkoxy,  $C_{1-6}$  haloalkoxy,  $C_{3-6}$  cycloalkyl,  $C_{5-6}$  cycloalkenyl,  $S(C_{1-4} \text{ alkyl})$ ,  $S(O)(C_{1-4} \text{ alkyl})$ ,

25  $S(O)_2(C_{1-4} \text{ alkyl})$ , heteroaryl, phenyl, heteroaryloxy or phenyloxy),  $C_{3-7}$  cycloalkyl, phenyl or heteroaryl; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro,  $S(C_{1-4} \text{ alkyl})$ ,  $S(O)(C_{1-4} \text{ alkyl})$ ,  $S(O)_2(C_{1-4} \text{ alkyl})$ ,  $S(O)_2NH_2$ ,  $S(O)_2NH(C_{1-4} \text{ alkyl})$ ,  $S(O)_2N(C_{1-4} \text{ alkyl})_2$ , cyano,  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy,  $C(O)NH_2$ ,  $C(O)NH(C_{1-4} \text{ alkyl})$ ,  $C(O)N(C_{1-4} \text{ alkyl})_2$ ,  $CO_2H$ ,  $CO_2(C_{1-4} \text{ alkyl})$ ,  $NHC(O)(C_{1-4} \text{ alkyl})$ ,  $NHS(O)_2(C_{1-4} \text{ alkyl})$ ,  $C(O)(C_{1-4} \text{ alkyl})$ ,  $CF_3$  or  $OCF_3$ ;

30  $R^{21}$ ,  $R^{23}$ ,  $R^{25}$ ,  $R^{28}$ ,  $R^{30}$ ,  $R^{34}$ ,  $R^{35}$ ,  $R^{36}$ ,  $R^{41}$ ,  $R^{42}$ ,  $R^{43}$ ,  $R^{44}$ ,  $R^{45}$ ,  $R^{46}$  and  $R^{47}$  may additionally be hydrogen;

or a pharmaceutically acceptable salt thereof or a solvate thereof.


2. A compound as claimed in claim 1 wherein A is absent.
- 5 3. A compound as claimed in claim 1 or 2 wherein n is 3.
4. A compound as claimed in claim 1, 2 or 3 wherein R<sup>1</sup> is piperidin-1-yl or piperazin-1-yl 4-substituted by, or piperidin-4-yl 1-substituted by, C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, phenyl {optionally substituted by, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, CF<sub>3</sub> or OCF<sub>3</sub>}, S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), S(O)<sub>2</sub>(C<sub>1-4</sub> fluoroalkyl), S(O)<sub>2</sub>phenyl {optionally substituted by halo, cyano, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, CF<sub>3</sub>, OCF<sub>3</sub>, S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl) or S(O)<sub>2</sub>(C<sub>1-4</sub> fluoroalkyl)}, benzyl {optionally substituted by halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, CF<sub>3</sub> or OCF<sub>3</sub>}, C(O)H, C(O)(C<sub>1-4</sub> alkyl), benzoyl {optionally substituted by halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, CF<sub>3</sub> or OCF<sub>3</sub>}, C(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), C(O)NH<sub>2</sub>, C(O)NH(C<sub>1-4</sub> alkyl) or C(O)NHphenyl {optionally substituted by halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, CF<sub>3</sub> or OCF<sub>3</sub>}.
- 10 15 5. A compound as claimed in claim 1, 2, 3 or 4 wherein R<sup>2</sup> is phenyl optionally substituted by halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, S(O)<sub>q</sub>(C<sub>1-4</sub> alkyl), nitro, cyano or CF<sub>3</sub>; wherein q is 0, 1 or 2.
- 20 6. A compound as claimed in any preceding claim wherein R<sup>3</sup> is hydrogen.
7. A compound as claimed in any preceding claim wherein R<sup>4</sup> is phenyl optionally substituted by halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, S(O)<sub>s</sub>(C<sub>1-4</sub> alkyl), nitro, cyano or CF<sub>3</sub>; wherein s is 0, 1 or 2.
- 25 8. A process for preparing a compound as claimed in claim 1, the process comprising
  - a. when R<sup>1</sup> is an N-linked optionally substituted heterocycle, reacting a compound of formula (II):




37

wherein  $R^2$ ,  $R^3$ ,  $R^4$ ,  $n$  and  $A$  are as defined in claim 1, with a compound  $R^1H$  (wherein the  $H$  is on a heterocycle ring nitrogen atom and  $R^1$  is as defined in claim 1), in the presence of a suitable base, in a suitable solvent and, for example, at a room temperature; OR,

- 5      b. when  $R^3$  is hydrogen, coupling a compound of formula (III):



wherein  $R^4$ ,  $n$  and  $A$  are as defined in claim 1, with a compound of formula (IV):



- 10      wherein  $R^1$  and  $R^2$  are as defined in claim 1, in the presence of  $NaBH(OAc)_3$  (wherein  $Ac$  is  $C(O)CH_3$ ) in a suitable solvent at room temperature.

9.      A pharmaceutical composition which comprises a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof or solvate thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier.
- 15
10.     A compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof or solvate thereof, for use as a medicament.
- 20
11.     A compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof or solvate thereof, in the manufacture of a medicament for use in therapy.
12.     A method of treating a CCR5 mediated disease state comprising administering to a patient in need of such treatment an effective amount of a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof or solvate thereof.
- 25